CTOs on the Move

Massachusetts Medical Society

www.massmed.org

 
The Massachusetts Medical Society is the oldest, most distinguished and prestigious continuously operating state medical association in the United States and the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.massmed.org
  • 860, Winter Street
    Waltham, MA USA 02451
  • Phone: 800.322.2303

Executives

Name Title Contact Details
Jacqui Boire
Director, Technology Strategy and Planning Profile

Similar Companies

Aerodyne Research

Aerodyne Research is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AlliancePharma

The vision of AlliancePharma Inc. is to offer a service that is human, professional and personalized, and fosters the development of the skills of the replacement pharmacists and pharmacy technicians. In the long term, AlliancePharma Inc. strives to increase and improve the value of its privileged position in the area of pharmacy replacement services, as well as diversifying its activities in high value added sectors linked to health.

Virtus Pharmaceuticals

Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.